Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- N/A
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
- Status
- RECRUITING
- Phase
- PHASE3
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Status
- RECRUITING
- Phase
- PHASE3
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- RECRUITING
- Phase
- PHASE3
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3